Problem

Relevium Medical is addressing chronic pain from knee osteoarthritis, a progressive and currently incurable condition that increasingly causes disability and affects the whole joint. The economic opportunity is substantial: the knee osteoarthritis market is described as multibillion-euro, while many patients still depend on oral pain medication, repeat injections, and, as the disease worsens, potentially addictive high-dose opioids. The principal use case is a patient with moderate-to-severe knee osteoarthritis who needs durable pain control without repeated procedures or systemic analgesics.

Product / Service

Relevium is developing a portfolio of pharmacological hydrogel therapies, led by RM-010, an injectable treatment delivered directly into the knee joint. Its platform combines natural biopolymers with active pharmaceutical agents. RM-010 is designed to gradually release a capsaicin analogue at concentrations below the level that causes burning while maintaining sufficient exposure to selectively ablate pain-sensing nerves; the company says the procedure can fit into a roughly five-minute clinical workflow.

The intended benefit is targeted, long-lasting pain relief, with the company describing relief lasting up to six months from an injection and substantially longer than existing approaches. The broader platform is intended to support additional chronic-pain applications, including bladder pain and interstitial cystitis, while other disclosed candidates address trauma-wound infection and postoperative pain.

Market

Relevium competes in biopharmaceutical chronic-pain therapeutics and injectable osteoarthritis treatments, particularly against the established treatment pattern of repeat joint injections and oral analgesics, including opioids. Its differentiation is a physician-administered hydrogel intended to combine local drug delivery, nerve-targeted pain relief, and longer duration in a single treatment. The company’s pipeline also gives it potential exposure to adjacent joint and chronic-pain indications.

The company appears pre-commercial rather than revenue-generating: the public evidence identifies completed preclinical testing and plans to fund its first clinical trials and manufacturing scale-up, but does not show a launched product or commercial revenue. Relevium was founded in 2019 as a University of Galway spinout, received Y Combinator support, reported €3.4 million raised by June 2024, and secured a separate €4.6 million government-backed project award for knee-osteoarthritis development. These are meaningful R&D and financing milestones, but the evidence supports development-stage traction rather than market sales.